This study evaluates the efficacy and safety and population PK of HMS5552 as monotherapy in type 2 diabetic adult subjects, there will be 2 groups in the first 24 weeks, one group will receive HMS5552 , while the other group will receive placebo ; after 24 weeks, all subjects received HMS5552 for 28 weeks.